MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.medj.2025.100802

Медицинская библиотека · Med (New York, N.Y.) · 2025

Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.

Fu Yakai, Chen Zhiwei, Chen Jie, Wu Wanlong, Gu Liyang, Ma Yiyangzi, Wang Runci, Wang Kaiwen, Xie Cuiying, Chen Yi, Cai Jiayi, Fu Qiong, Wang Xiaodong, Ye Shuang

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) with rapidly progressive interstitial lung disease (RPILD) is a fatal disease. Although Janus kinase inhibitors (JAKi) hold their promise in treating MDA5+ DM, regimen for RPILD is still urgently needed to improve the adverse prognosis.

METHODS

Based on a large inception cohort of MDA5+ DM, patients with RPILD (oxygen index [OI] < 300 within the first 3 months of disease duration) were included. Patients who received protein A immunoadsorption plus a JAKi were compared to those treated with JAKi alone. Propensity score matching (PSM) was performed to adjust confounding factors. Survival analysis was conducted to evaluate the efficacy of immunoadsorption add-on.

FINDINGS: From October 2017 to April 2024, a total of 152 newly diagnosed MDA5+ DM patients with RPILD were eligible for analyses. Thirty-four patients who underwent immunoadsorption with JAKi (ProJAK group) and 68 patients who received JAKi with or without other immunosuppressants combination (JAK group) as controls were compared after 1:2 PSM. The 6-month transplantation-free survival was significantly improved from 16.2% in the JAK group to 41.2% in the ProJAK group (p = 0.004). Subgroup analysis suggested that ProJAK therapy tended to have a more significant survival gain in patients with OI < 200. The most common adverse effect of ProJAK was transient immunoglobin decrease, but the infectious rate was similar between the 2 groups.

CONCLUSIONS

Immunoadsorption in combination with JAKi might be a promising treatment approach for MDA5+ DM patients with RPILD.

FUNDING: This work was supported by NFSC and SHDC.

Для цитирования: Fu Yakai, Chen Zhiwei, Chen Jie, Wu Wanlong, Gu Liyang, Ma Yiyangzi, Wang Runci, Wang Kaiwen, Xie Cuiying, Chen Yi, Cai Jiayi, Fu Qiong, Wang Xiaodong, Ye Shuang. Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.. Med (New York, N.Y.). 2025. DOI: 10.1016/j.medj.2025.100802.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.